Here's some more proving that people do leave Trials if they have adverse reactions,
Which Giddy falsely stated doesn't happen:
"Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs)"
Easy with Patience, page-117
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.001(5.26%) |
Mkt cap ! $18.04M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $34.45K | 1.717M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1537498 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 2245665 | 5 |
View Market Depth
| Last trade - 14.20pm 09/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |